The College of Pharmacy at the University of Basrah discussed a Master's thesis titled "Evaluating the Safety and Efficacy of Combining Dapagliflozin and Furosemide in Individuals with Acute Heart Failure and Type 2 Diabetes," presented by the student Hanaa Jassim Dhi Duhi Abdul Nabi.
The thesis studied the inhibitor Dapagliflozin (Sodium-Glucose Co-transporter 2 inhibitor), which facilitates treatment during early hospitalization for acute heart failure by aiding sodium excretion in urine, decongestion, and ensuring a safe transition to effective outpatient therapy for both diabetes and heart failure.
The study aimed to determine whether the treatment is safe and effective in improving clinical and biochemical parameters within the first 24 hours in patients with ADHF and Type 2 Diabetes (DMII) who have a low left ventricular ejection fraction.
The study concluded that initiating Dapagliflozin early in the treatment course for hospitalized patients with heart failure facilitates decongestion and improves weight loss and dyspnea. Furthermore, it can reduce heart failure re-hospitalization across a wide range of patients without any significant decline in renal function.
